APOA1 and atherosclerosis: The AIM-HIGH trial with patients with previous ASCVD on statin treatment in combination with niacin, showed that Lp(a) was a risk factor for recurrent ASCVD in the group with combination therapy and in the control group (only statins), whereas apoB and apoA-I (corresponding to all atherogenic lipoprotein particles and corresponding to HDL particle number, respectively) were only predictive for recurrent ASCVD in the control group, suggesting an independent role for Lp(a) in relation to ASCVD (91, 92).